Gilead (GILD) 2025 — Grade F: HIV Cash Machine vs $25.3B Acquisition Intangibles

Grade: F — Major Red Flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Fiscal year ended December 31, 2025) + Yahoo Finance

Auditor: Ernst & Young LLP — Clean opinion (1 critical audit matter: government and commercial rebates)

One-line verdict: Gilead's F grade is driven by structural balance sheet characteristics common in big pharma — $24.9B in debt (39% cash coverage) and $25.3B in goodwill plus intangibles (111% of equity) from past acquisitions. The underlying business is healthy: net income recovered to $8.5B from a depressed $480M in FY2024 (which was dragged down by $3.8B in CymaBay IPR&D charges and $4.2B in Immunomedics-related impairments). CFFO of $10.0B, clean M-Score of -2.45, and 78.8% gross margins confirm a high-quality franchise. The rebate estimation system flagged by EY as the critical audit matter is the real area to watch.

The HIV and Oncology Franchise

Gilead Sciences is a biopharmaceutical company focused on HIV, liver disease, oncology, and inflammation. In FY2025, the company introduced Yeztugo, described in the 10-K as "the first and only twice-yearly HIV pre-exposure prophylaxis (PrEP) option available in the U.S." and expanded Livdelzi's market share in primary biliary cholangitis treatment.

From the 10-K: "Total revenues increased 2% to $29.4 billion in 2025, compared to 2024, primarily due to higher product sales primarily driven by HIV and Liver Disease products, partially offset by lower sales of Veklury."

The dramatic net income swing — from $480M in FY2024 to $8.5B in FY2025 — was primarily driven by non-recurring items in FY2024. Per the filing: "The increase was primarily due to a $3.8 billion acquired in-process research and development (IPR&D) expense related to the acquisition of CymaBay Therapeutics, Inc. in 2024, which did not repeat in 2025; Lower pre-tax IPR&D partial impairment charges, with $590 million in 2025 related to assets acquired from MYR GmbH compared to $4.2 billion in 2024 related to assets acquired from Immunomedics, Inc."

The Impairment Story

This is critical context for earnings quality: FY2024 net income of $480M was not a reflection of the business deteriorating — it was a reflection of two massive write-downs:

The 10-K warns about future risk: "In November 2025, we also announced that our Phase 3 ASCENT-07 study evaluating SG as a first-line treatment post-endocrine therapy in HR+/HER2- metastatic breast cancer patients did not meet the primary endpoint of progression-free survival. While this information did not result in an impairment of the associated finite-lived intangible asset related to Trodelvy, potential future adverse changes in estimated Trodelvy revenues could negatively impact our results of operations and result in impairment charges in future periods."

Cash Flow: Rock-Solid Despite Revenue Plateau

CFFO/NI of 1.18 in FY2025 confirms that the $8.5B net income is well-supported by cash. The FY2024 ratio of 22.56x was an anomaly — $10.8B in cash from a business reporting only $480M in net income, because the write-downs that crushed net income were non-cash charges. This actually confirms earnings quality: the cash-generating engine continued humming regardless of accounting charges.

FCF of $9.5B comfortably covers the dividend ($370M initiated in FY2025) and share repurchases.

The $25.3B in Goodwill and Intangibles

Goodwill of $8.3B and intangible assets of $17.0B total $25.3B, representing 111% of stockholders' equity of $22.6B. This is the product of Gilead's acquisition history — primarily the $21B Immunomedics acquisition (2020) for Trodelvy and the $12B Pharmasset acquisition (2011) for Sovaldi/Harvoni.

Goodwill plus intangibles declined 11% YoY, driven by ongoing amortization and the $590M MYR-related impairment. This is the opposite of the goodwill-building pattern that signals serial acquirer risk.

The intangible assets are finite-lived and amortizing — they are not indefinite-lived goodwill sitting on the balance sheet without amortization. As drug patents expire and intangibles amortize, this ratio will improve over time absent new large acquisitions.

The 18-Point Screening

Revenue Quality

A2: AR grew nearly 5x faster than revenue. In pharma, this can reflect changes in payer mix, government rebate timing, or channel dynamics. The 10-K identifies that revenue reductions for government and commercial rebates require significant estimation. EY flagged this as the critical audit matter: "Auditing the Company's estimated reductions to revenue for rebates was complex and involved significant judgment, particularly in assessing the reasonableness of estimated payer mix applied to sales during the period." Slower rebate collection or shifting payer mix could temporarily inflate AR relative to net revenue.

Expense Quality

All expense quality checks pass cleanly. The 78.8% gross margin is characteristic of a branded pharma franchise with significant pricing power. SG&A discipline at 24.6% of gross profit is excellent.

Cash Flow Quality

C4: Cash of $9.6B covers only 39% of the $24.9B debt stack. However, Debt/EBITDA is a modest 1.8x with 11.4x interest coverage. Gilead is actively deleveraging — debt decreased from $25.2B (FY2023) to $24.9B (FY2025). With $9.5B in annual FCF, the debt is manageable.

Balance Sheet

D3: Soft asset growth of 28.5% outpaced revenue by 12x. This warrants investigation — the growth could reflect increased deferred tax assets, prepaid royalties, or other items that grew disproportionately. Given the clean accruals ratio (-2.6%) and strong cash conversion, this is likely timing-related rather than indicative of aggressive accounting.

M&A Risk

Beneish M-Score

All M-Score components are benign: DSRI 1.086, GMI 0.993, SGAI 0.929. No individual component approaches warning levels.

Critical Audit Matter: Rebate Estimation

EY identified government and commercial rebates as the sole critical audit matter: "The Company estimates reductions to its revenues for amounts payable to payers and healthcare providers in the United States under various government and commercial rebate programs in the period that the related sales occur. Rebates may vary by product, payer and individual payer plans, some of which may not be known at the point of sale."

The audit firm noted: "Auditing the Company's estimated reductions to revenue for rebates was complex and involved significant judgment, particularly in assessing the reasonableness of estimated payer mix applied to sales during the period. This estimate relies heavily on historical data that is adjusted for changes in payer mix expectations over time."

This is the most critical earnings quality consideration for Gilead. The spread between gross product sales and net revenue (after rebates) is enormous in pharma. Small shifts in payer mix assumptions can meaningfully impact reported revenue.

Key Risks from Item 1A

1. Pipeline concentration risk. The 10-K states that Gilead has "over 50 clinical-stage programs across our core therapeutic areas." However, the ASCENT-07 Phase 3 failure for Trodelvy in first-line breast cancer signals execution risk. Future impairment charges on Trodelvy remain possible.

2. Lenacapavir is the growth catalyst — and it's not yet approved for PrEP. The filing describes lenacapavir as "a once-yearly injection of lenacapavir, an HIV-1 capsid inhibitor, being evaluated for HIV PrEP." If approved, this could be transformative. If it fails, growth stalls.

3. Veklury decline. COVID-related Veklury revenues are expected to continue declining. The 10-K outlook states: "an expected decrease in our Veklury product sales due to lower rates of COVID-19-related hospitalizations."

4. Pricing pressure. The Inflation Reduction Act's Medicare drug price negotiation provisions will increasingly impact Gilead's revenue. The company flags "expectations regarding the impact of the Inflation Reduction Act and the One Big Beautiful Bill Act, changes in U.S. regulatory policies."

Altman Z-Score and F-Score

Both models confirm financial health. The Z-Score places Gilead firmly in the safe zone, and the F-Score's low probability (0.47%) indicates minimal fraud risk. The primary F-Score contributor is the high soft asset ratio (0.78), reflecting intangible-heavy pharma balance sheets.

Summary

Grade: F. The grade reflects pharma balance sheet structure, not operational weakness.

Gilead's F is driven by two structural characteristics common across big pharma: acquisition-related intangibles (111% of equity) and a debt load (39% cash coverage) accumulated to finance those acquisitions. The business itself is strong:

The risk is not today's numbers — it is future pipeline execution. Trodelvy faces further impairment risk, Veklury is declining, and lenacapavir PrEP approval is not guaranteed. The balance sheet can absorb more write-downs ($22.6B equity, $9.5B annual FCF), but another FY2024-sized charge would test investor patience.

**Disclaimer**: This report is based on Gilead's FY2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

Data: SEC EDGAR 10-K (Fiscal year ended December 31, 2025) + Yahoo Finance

Auditor: Ernst & Young LLP (Unqualified opinion, 1 critical audit matter)